Do you want to read an article? Please log in or register.
Sodium-glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis - A Multi-site Prevalent New-user Cohort Study
Type 2 Diabetes
Related content
COMMENTED
Type 2 Diabetes
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
BMJ.
Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B
doi: 10.1136/bmj.k4365.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
JAMA Intern Med.
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC
doi: 10.1001/jamainternmed.
Type 2 Diabetes
Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study
Diabetes Obes Metab.
Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T
doi: 10.1111/dom.14189.
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.
Diabetes - GeneralGlycemic Control
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis
J Am Heart Assoc.
Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL
doi: 10.1161/JAHA.117.005686.
COMMENTED
Type 2 Diabetes
Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors
doi: 10.1210/clinem/dgaa200.
Type 2 Diabetes
Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study
Ann Intern Med.
Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E
doi: 10.7326/M18-0567.
Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study
Diabetologia.
But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A, Starup-Linde J, Schmidt MK, Furu K, de Vries F, Karlstad Ø, Ekström N, Haukka J
doi: 10.1007/s00125-017-4312-5.
COMMENTED
Type 1 Diabetes
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
Diabetes Care.
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M
doi: 10.2337/dc18-